Gabriella Fontanini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8118049/publications.pdf

Version: 2024-02-01

221 papers	9,106 citations	38742 50 h-index	53230 85 g-index
224 all docs	224 docs citations	224 times ranked	10495 citing authors

#	Article	IF	Citations
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. Journal of Clinical Pathology, 2023, 76, 47-52.	2.0	9
2	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. Journal of Clinical Pathology, 2022, 75, 416-421.	2.0	6
3	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	2.4	15
4	Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. Diagnostics, 2022, 12, 477.	2.6	10
5	Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers. Diagnostics, 2022, 12, 674.	2.6	2
6	Inflammatory Profiles of Tracheal Biopsies From SARS-CoV-2 Patients. Frontiers in Microbiology, 2022, 13, 851460.	3.5	2
7	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. Cancer Treatment Reviews, 2022, 106, 102382.	7.7	9
8	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2022, 23, 876-887.	10.7	83
9	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. Journal of Clinical Oncology, 2022, 40, 2878-2888.	1.6	24
10	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. Journal of Clinical Pathology, 2021, 74, 391-395.	2.0	17
11	Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma. Journal of Chemotherapy, 2021, 33, 198-202.	1.5	5
12	Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the â€œProgrammed Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinomaâ€• Journal of Pathology Informatics, 2021, 12, 1.	1.7	22
13	Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. Expert Review of Anticancer Therapy, 2021, 21, 887-900.	2.4	4
14	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. European Journal of Cancer, 2021, 146, 74-83.	2.8	29
15	Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation. Frontiers in Oncology, 2021, 11, 674604.	2.8	2
16	Feasibility of BRCA1/2 Testing of Formalin-Fixed and Paraffin-Embedded Pancreatic Tumor Samples: A Consecutive Clinical Series. Diagnostics, 2021, 11, 1046.	2.6	4
17	Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 3828.	3.7	6
18	In Reply. Oncologist, 2021, 26, e1895-e1896.	3.7	0

#	Article	IF	Citations
19	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica, 2021, 113, 262-271.	3.4	13
20	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. European Journal of Cancer, 2021, 153, 16-26.	2.8	5
21	Prevalence of Delta-Like Protein 3 in a Consecutive Series of Surgically Resected Lung Neuroendocrine Neoplasms. Frontiers in Oncology, 2021, 11, 729765.	2.8	9
22	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 2021, 13, 4875.	3.7	7
23	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. European Journal of Cancer, 2021, 155, 73-84.	2.8	13
24	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2021, 165, 103436.	4.4	40
25	Conventional Transbronchial Needle Aspiration (cTBNA) and EBUS-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Retrospective Study on the Comparison of the Two Methods for Diagnostic Adequacy in Molecular Analysis. Journal of Molecular Pathology, 2021, 2, 296-305.	1.2	2
26	Expression of miRNA-25 in young and old lung adenocarcinoma. Journal of Research in Medical Sciences, 2021, 26, 132.	0.9	2
27	Distinct Angiogenic microRNA-mRNA Expression Profiles Among Subtypes of Lung Adenocarcinoma. Pathology and Oncology Research, 2020, 26, 1089-1096.	1.9	2
28	Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study. International Journal of Colorectal Disease, 2020, 35, 9-18.	2.2	21
29	Laryngotracheal resection for a post-tracheotomy stenosis in a patient with coronavirus disease 2019 (COVID-19). JTCVS Techniques, 2020, 4, 360-364.	0.4	14
30	Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review. Diagnostics, 2020, 10, 521.	2.6	83
31	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	2.4	47
32	Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. Pharmacological Research, 2020, 158, 104920.	7.1	12
33	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. European Journal of Cancer, 2020, 135, 78-88.	2.8	10
34	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 497-507.	10.7	196
35	Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation. Journal of Molecular Diagnostics, 2020, 22, 685-698.	2.8	11
36	Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record. Cancers, 2020, 12, 1800.	3.7	12

#	Article	IF	Citations
37	Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology. Journal of Molecular Diagnostics, 2020, 22, 457-466.	2.8	7
38	Crizotinib in ROS1 and MET Deregulated NSCLCâ€"Response. Clinical Cancer Research, 2020, 26, 1775-1775.	7.0	2
39	Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.. Journal of Clinical Oncology, 2020, 38, 4016-4016.	1.6	6
40	Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study.. Journal of Clinical Oncology, 2020, 38, 4077-4077.	1.6	1
41	A geneâ€'expressionâ€'based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations. Oncology Letters, 2020, 19, 1060-1065.	1.8	3
42	Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer. American Journal of Cancer Research, 2020, 10, 2120-2127.	1.4	0
43	Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 153-158.	2.4	30
44	Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Nonâ€"Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. Clinical Cancer Research, 2019, 25, 7312-7319.	7.0	139
45	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. Journal of Thoracic Oncology, 2019, 14, 1651-1661.	1.1	73
46	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	2.4	39
47	Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. Journal of Experimental and Clinical Cancer Research, 2019, 38, 108.	8.6	34
48	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. Scientific Reports, 2019, 9, 3536.	3.3	11
49	Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	7.0	67
50	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. Biochemical Pharmacology, 2019, 164, 94-105.	4.4	14
51	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. European Journal of Cancer, 2019, 109, 175-182.	2.8	25
52	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. European Journal of Cancer, 2019, 110, 32-41.	2.8	25
53	Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. British Journal of Cancer, 2019, 120, 522-526.	6.4	11
54	Pathological Diagnosis of Mesothelioma. , 2019, , 99-122.		0

#	Article	IF	Citations
55	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 567-577.	2.8	64
56	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer. JAMA Oncology, 2018, 4, 529.	7.1	87
57	Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. Archives of Pathology and Laboratory Medicine, 2018, 142, 480-489.	2.5	33
58	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. Cancer Biomarkers, 2018, 21, 731-741.	1.7	16
59	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. British Journal of Cancer, 2018, 118, 955-965.	6.4	17
60	Diaphragm and lungâ€“preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1857-1866.e2.	0.8	37
61	Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. Journal of Thoracic Disease, 2018, 10, S342-S352.	1.4	23
62	Surgery for malignant pleural mesothelioma: an international guidelines review. Journal of Thoracic Disease, 2018, 10, S285-S292.	1.4	37
63	In Reply. Archives of Pathology and Laboratory Medicine, 2018, 142, 1452-1452.	2.5	0
64	Expression profiling and microRNA regulation of the LKB1 pathway in young and aged lung adenocarcinoma patients. Biomedical Reports, 2018, 9, 198-205.	2.0	2
65	The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. Journal of Thoracic Disease, 2018, 10, S276-S284.	1.4	39
66	Screen-detected multiple primary lung cancers in the ITALUNG trial. Journal of Thoracic Disease, 2018, 10, 1058-1066.	1.4	16
67	N2 lung cancer is not all the same: an analysis of different prognostic groupsâ€. Interactive Cardiovascular and Thoracic Surgery, 2018, 27, 720-726.	1.1	13
68	Hippo pathway affects survival of cancer patients: extensive analysis of TCGA data and review of literature. Scientific Reports, 2018, 8, 10623.	3.3	25
69	Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. Journal of Clinical Oncology, 2018, 36, 636-636.	1.6	0
70	The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.. Journal of Clinical Oncology, 2018, 36, e15593-e15593.	1.6	0
71	Abstract 1823: Identification of molecular determinants of vinorelbine resistance in BRAF(V600E) mutated chemorefractory metastatic colorectal cancer patients. , 2018, , .		0
72	Prognostic role of TPL2 in early-stage non-small cell lung cancer. Molecular Medicine Reports, 2017, 15, 3451-3458.	2.4	3

#	Article	IF	Citations
73	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36Âmonths. Experimental Hematology and Oncology, 2017, 6, 6.	5.0	38
74	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research, 2017, 23, 4312-4322.	7.0	41
75	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. European Journal of Cancer, 2017, 73, 74-84.	2.8	54
76	Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. Cancer Letters, 2017, 411, 35-43.	7.2	25
77	KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3091-3096.	3.6	2
78	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. Annals of Oncology, 2017, 28, iii94-iii95.	1.2	0
79	Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by GeneXpert MTB/RIF. Tuberculosis, 2017, 106, 53-55.	1.9	12
80	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatinâ€remodelling genes as major players and a prognostic role for <scp>TERT</scp>, <scp>RB1</scp>, <scp>MEN1</scp> and <scp>KMT2D</scp>. Journal of Pathology, 2017, 241, 488-500.	4.5	179
81	Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report. Oncology Letters, 2017, 14, 5947-5951.	1.8	16
82	Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Genes and Cancer, 2017, 8, 438-452.	1.9	18
83	Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma. Cancer Cell International, 2017, 17, 105.	4.1	38
84	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Scientific Reports, 2017, 7, 9388.	3.3	56
85	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	2.4	58
86	Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study.. Journal of Clinical Oncology, 2017, 35, 11508-11508.	1.6	1
87	Novel prognostic markers for epithelioid malignant pleural mesothelioma.. Journal of Clinical Oncology, 2017, 35, e20028-e20028.	1.6	3
88	MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations.. Journal of Clinical Oncology, 2017, 35, e20656-e20656.	1.6	1
89	Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Oncotarget, 2017, 8, 2758-2770.	1.8	26
90	Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) inRASandBRAFwild-type (wt) metastatic colorectal cancer (mCRC). , 2017, , .		0

#	Article	IF	Citations
91	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 2016, 36, 1166-1172.	2.6	15
92	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist, 2016, 21, 988-994.	3.7	94
93	Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma. Oncology Letters, 2016, 12, 4009-4012.	1.8	15
94	Aberrant expression of anaplastic lymphoma kinase in lung adenocarcinoma: Analysis of circulating free tumor RNA using one-step reverse transcription-polymerase chain reaction. Molecular Medicine Reports, 2016, 14, 2238-2242.	2.4	1
95	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. British Journal of Cancer, 2016, 114, 30-36.	6.4	56
96	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. Journal of Clinical Oncology, 2016, 34, 3543-3543.	1.6	9
97	Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors. , 2016, , .		0
98	The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. Journal of Translational Medicine, 2015, 13, 287.	4.4	14
99	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	2.6	10
100	microRNA classifiers are powerful diagnostic/prognostic tools in ALK- , EGFR- , and KRAS -driven lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14924-14929.	7.1	74
101	Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. Modern Pathology, 2015, 28, 487-497.	5.5	59
102	Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report. Oncology Letters, 2015, 9, 1537-1540.	1.8	7
103	Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 177-184.	2.8	59
104	P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncology Letters, 2015, 9, 449-453.	1.8	24
105	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	10.7	835
106	Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer. International Journal of Cancer, 2015, 136, 83-90.	5.1	126
107	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. Journal of Clinical Oncology, 2015, 33, 3510-3510.	1.6	8
108	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget, 2015, 6, 31604-31612.	1.8	30

#	Article	IF	Citations
109	Gene promoter methylation in colorectal cancer and healthy adjacent mucosa specimens. Epigenetics, 2014, 9, 621-633.	2.7	47
110	P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). Journal of Negative Results in BioMedicine, 2014, 13, 16.	1.4	15
111	EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. Journal of Experimental and Clinical Cancer Research, 2014, 33, 77.	8.6	13
112	KRAS and BRAF genotyping of synchronous colorectal carcinomas. Oncology Letters, 2014, 7, 1532-1536.	1.8	7
113	ALKRearrangement in a Large Series of Consecutive Nonâ€“Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Archives of Pathology and Laboratory Medicine, 2014, 138, 1449-1458.	2.5	93
114	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Molecular and Cellular Endocrinology, 2014, 393, 56-64.	3.2	21
115	MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies. Clinical Colorectal Cancer, 2014, 13, 37-45.e4.	2.3	46
116	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	3.6	27
117	CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E572-E581.	3.6	46
118	Anaplastic lymphoma kinase gene rearrangements in cytological samples of nonâ€“small cell lung cancer: Comparison with histological assessment. Cancer Cytopathology, 2014, 122, 445-453.	2.4	40
119	Recurrent Spontaneous Pneumothorax Hiding a Rare Pulmonary Tumor in a 4-Year-Old Girl. Annals of Thoracic Surgery, 2014, 98, 1847.	1.3	0
120	Novel MTCYB mutation in a young patient with recurrent strokeâ€like episodes and status epilepticus. American Journal of Medical Genetics, Part A, 2014, 164, 2922-2925.	1.2	6
121	Mutant cohesin drives chromosomal instability in early colorectal adenomas. Human Molecular Genetics, 2014, 23, 6773-6778.	2.9	30
122	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1783-1793.	2.5	8
123	A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics, 2014, 46, 844-849.	21.4	208
124	Management of Italian Patients With Advanced Nonâ€“Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study. Clinical Lung Cancer, 2014, 15, 338-345.e1.	2.6	7
125	Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. Journal of Clinical Oncology, 2014, 32, 3519-3519.	1.6	9
126	Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. Journal of Clinical Oncology, 2014, 32, 3596-3596.	1.6	4

#	Article	IF	Citations
127	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 476-476.	1.6	0
128	Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1465-E1473.	3.6	33
129	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer, 2013, 81, 377-381.	2.0	8
130	An â€œinflammatoryâ€•mitochondrial myopathy. A case report. Neuromuscular Disorders, 2013, 23, 907-910.	0.6	13
131	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report. Lung Cancer, 2013, 81, 297-301.	2.0	10
132	Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. International Journal of Oncology, 2013, 43, 765-774.	3.3	53
133	Differential Expression of Extracellular Matrix Constituents and Cell Adhesion Molecules between Malignant Pleural Mesothelioma and Mesothelial Hyperplasia. Journal of Thoracic Oncology, 2013, 8, 1389-1395.	1.1	25
134	Glomus tumor of the shoulder: A case report and review of the literature. Oncology Letters, 2013, 6, 1021-1024.	1.8	19
135	Phosphatidylinositol-3-kinase Î± catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncology Reports, 2012, 28, 1559-1566.	2.6	19
136	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 520-527.	1.1	19
137	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E528-E536.	3.6	49
138	Malignancies Within Rhinophyma: Report of Three New Cases and Review of the Literature. Aesthetic Plastic Surgery, 2012, 36, 396-405.	0.9	31
139	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. Cancer Chemotherapy and Pharmacology, 2012, 69, 1407-1412.	2.3	9
140	Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo. Neoplasia, 2011, 13, 217-IN3.	5.3	31
141	Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Experimental and Therapeutic Medicine, 2011, 2, 787-792.	1.8	23
142	Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2011, 6, 395-396.	1.1	44
143	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E288-E296.	3.6	71
144	Thermal Ablation of Lung Tissue: In Vivo Experimental Comparison of Microwave and Radiofrequency. CardioVascular and Interventional Radiology, 2010, 33, 818-827.	2.0	52

#	Article	IF	Citations
145	Î”N133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Human Mutation, 2010, 31, 456-465.	2.5	21
146	Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?â˜†. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 572-576.	1.1	8
147	BRAFStatus of Follicular Variant of Papillary Thyroid Carcinoma and its Relationship to Its Clinical and Cytological Features. Thyroid, 2010, 20, 1263-1270.	4.5	31
148	CXC Chemokine Receptor 4 Immunodetection in the Follicular Variant of Papillary Thyroid Carcinoma: Comparison to Galectin-3 and Hector Battifora Mesothelial Cell-1. Thyroid, 2010, 20, 495-504.	4.5	24
149	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 845-852.	10.7	234
150	Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 167-181.	3.2	7
151	Advances in molecular diagnostics for mitochondrial diseases. Expert Opinion on Medical Diagnostics, 2009, 3, 557-569.	1.6	0
152	Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncology Reports, 2009, 22, 683-91.	2.6	25
153	Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics, 2009, 10, 1225-1229.	1.3	7
154	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. European Journal of Pharmacology, 2009, 619, 8-14.	3.5	35
155	Laser capture microdissection: A tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. International Journal of Molecular Medicine, 2009, 24, 473-9.	4.0	3
156	Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor. Journal of Thoracic Oncology, 2009, 4, 348-354.	1.1	37
157	Different estrogen receptor Î² expression in distinct histologic subtypes of lung adenocarcinoma. Human Pathology, 2008, 39, 1465-1473.	2.0	40
158	Effect of the p53 Codon 72 and Intron 3Polymorphisms on Non-Small Cell Lung Cancer (NSCLC) Prognosis. Cancer Investigation, 2008, 26, 168-172.	1.3	20
159	Intraoperative sentinel lymph node mapping in stage I non-small cell lung cancer: detection of micrometastases by polymerase chain reaction. European Journal of Cardio-thoracic Surgery, 2008, 34, 181-186.	1.4	41
160	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12468-12473.	7.1	63
161	A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage IIâ€“III malignant pleural mesotheliomaâ˜†. European Journal of Cardio-thoracic Surgery, 2007, 31, 529-534.	1.4	38
162	Expression of Cyclooxygenase-2 and Its Correlation with Vasogenic Brain Edema in Human Intracranial Meningiomas. Cancer Investigation, 2007, 25, 555-562.	1.3	11

#	Article	IF	Citations
163	WWOX Expression in Different Histologic Types and Subtypes of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 884-891.	7.0	58
164	Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis. Journal of Thoracic Oncology, 2007, 2, 1086-1090.	1.1	102
165	Four-Modality Therapy in Malignant Pleural Mesothelioma: A Phase II Study. Journal of Thoracic Oncology, 2007, 2, 237-242.	1.1	30
166	MERRF syndrome without ragged-red fibers: The need for molecular diagnosis. Biochemical and Biophysical Research Communications, 2007, 354, 1058-1060.	2.1	28
167	CDC25B: relationship with angiogenesis and prognosis in nonâ€“small cell lung carcinoma. Human Pathology, 2007, 38, 1563-1568.	2.0	11
168	Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 373-377.	0.8	47
169	Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenetics and Genomics, 2006, 16, 809-816.	1.5	29
170	Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 546-553.	2.8	14
171	Biologic effects of radiofrequency thermal ablation on nonâ€“small cell lung cancer: Results of a pilot study. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 1002-1006.	0.8	53
172	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. Journal of Cellular Physiology, 2006, 208, 344-353.	4.1	59
173	Percutaneous radiofrequency ablation of lung tumours: results in the mid-termâ˜†. European Journal of Cardio-thoracic Surgery, 2006, 30, 177-183.	1.4	121
174	Distal embolization during angioplasty for acute myocardial infarction: is pharmacological protection enough?. Thrombosis and Haemostasis, 2005, 94, 680-681.	3.4	1
175	Osteopontin Expression and Prognostic Significance in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 6459-6465.	7.0	98
176	Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. Clinical Cancer Research, 2005, 11, 5639-5644.	7.0	83
177	Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. European Journal of Cancer, 2005, 41, 2828-2835.	2.8	45
178	Advanced Stage Thymomas and Thymic Carcinomas: Results of Multimodality Treatments. Annals of Thoracic Surgery, 2005, 79, 1840-1844.	1.3	133
179	Distal embolization during primary angioplasty: Histopathologic features and predictability. American Heart Journal, 2005, 150, 102-108.	2.7	97
180	Interleukin-8 in non-small cell lung carcinoma: Relation with angiogenic pattern and p53 alterations. Lung Cancer, 2005, 50, 309-317.	2.0	31

#	Article	IF	Citations
181	Immunohistochemical and Molecular Study of Radiation-Induced Multiple Meningiomas with Pleural and Pulmonary Metastasis. Tumori, 2004, 90, 328-332.	1.1	4
182	Expression and Mutational Status of c-kit in Small-Cell Lung Cancer. Clinical Cancer Research, 2004, 10, 4101-4108.	7.0	87
183	Radiofrequency Ablation of Lung Malignancies: Where Do We Stand?. CardioVascular and Interventional Radiology, 2004, 27, 581-590.	2.0	56
184	Applications of tissue microarray technology in immunohistochemistry: A study on c-kit expression in small cell lung cancer. Human Pathology, 2004, 35, 1347-1352.	2.0	11
185	CD34 Microvessel Density and VEGF Expression in Basal and Squamous Cell Carcinoma. Pathology Research and Practice, 2003, 199, 705-712.	2.3	18
186	Mutations of Fas (APO-1/CD95) and p53 Genes in Nonmelanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery, 2003, 7, 112-118.	1.2	4
187	Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens. Thyroid, 2003, 13, 765-770.	4.5	51
188	Mechanical Prevention of Distal Embolization During Primary Angioplasty. Circulation, 2003, 108, 171-176.	1.6	147
189	Mutations of Fas (APO-1/CD95) and p53 Genes in Nonmelanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery, 2003, 7, 112-118.	1.2	10
190	The Role of Somatostatin in Vasogenic Meningioma Associated Brain Edema. Tumori, 2003, 89, 136-140.	1.1	10
191	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clinical Cancer Research, 2003, 9, 1546-56.	7.0	263
192	Small cell lung carcinoma (SCLC): the angiogenic phenomenon. European Journal of Cardio-thoracic Surgery, 2002, 21, 1105-1110.	1.4	124
193	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research, 2002, 62, 7284-90.	0.9	463
194	Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer. Oncogene, 2001, 20, 6632-6637.	5.9	22
195	Suppression of Fas Expression and Down-Regulation of Fas Ligand in Highly Aggressive Human Thyroid Carcinoma. Laboratory Investigation, 2000, 80, 1413-1419.	3.7	26
196	N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression. Thyroid, 2000, 10, 19-23.	4.5	159
197	Cyclin D1 Overexpression in Thyroid Carcinomas: Relation with Clinico-Pathological Parameters, Retinoblastoma Gene Product, and Ki67 Labeling Index. Thyroid, 2000, 10, 741-746.	4.5	50
198	Angiogenesis and Cancer. Surgical Technology International, 2000, IX, 25-32.	0.2	0

#	Article	IF	Citations
199	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of thebcl-2 gene. , 1999, 81, 956-962.		13
200	The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression. Human Pathology, 1999, 30, 788-794.	2.0	59
201	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of the bcl2 gene. International Journal of Cancer, 1999, 81, 956-962.	5.1	1
202	Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-11. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4094-4100.	3.6	38
203	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids, 1996, 10, 701-710.	2.2	42
204	Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA-N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence. , 1996, 78, 409-415.		60
205	Neoangiogenesis: A putative marker of malignancy in non-small-cell-lung-cancer (NSCLC) development. , 1996, 67, 615-619.		32
206	Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A. Journal of the National Cancer Institute, 1996, 88, 1770-1776.	6.3	109
207	Microvessel count predicts metastatic disease and survival in nonâ€small cell lung cancer. Journal of Pathology, 1995, 177, 57-63.	4.5	166
208	Human nonâ€small cell lung cancer: P53 protein accumulation is an early event and persists during metastatic progression. Journal of Pathology, 1994, 174, 23-31.	4.5	51
209	Response of normal and oncogene-transformed human mammary epithelial cells to transforming growth factor Î²1 (TGF-Î²1): Lack of growth-inhibitory effect on cells expressing the simian virus 40 large-t antigen. International Journal of Cancer, 1994, 56, 736-742.	5.1	25
210	Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer. European Journal of Cancer, 1994, 30, 171-174.	2.8	37
211	Angiogenesis: An indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Annals of Thoracic Surgery, 1994, 57, 1534-1539.	1.3	81
212	Angiogenic potential in vivo by KaposiÊ¼s sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. Aids, 1994, 8, 1237-1244.	2.2	147
213	Receptor Status, Proliferating Activity, and c-erbB2 Oncoprotein.. Annals of the New York Academy of Sciences, 1993, 698, 167-173.	3.8	4
214	Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 1993, 106, 80-88.	0.8	111
215	Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Journal of Thoracic and Cardiovascular Surgery, 1992, 104, 892-899.	0.8	55
216	The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer, 1992, 70, 1520-1527.	4.1	78

#	Article	IF	Citations
217	Morphology and Progression of Preneoplastic Changes in Methylcholanthrene-Induced Mouse Mammary Tumorigenesis. Tumori, 1985, 71, 1-11.	1.1	4
218	Factors that Affect Metastasis in Virus-Induced Mouse Mammary Tumors. Tumori, 1984, 70, 131-136.	1.1	0
219	Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. Molecular Medicine Reports, 0, , .	2.4	0
220	Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. Oncology Reports, 0, , .	2.6	2
221	Regulation of telomerase and its hTERT messenger in colorectal cancer. Oncology Reports, 0, , .	2.6	7